Shopping Cart 0
Cart Subtotal
AED 0

Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Pharma Mar SA (PHM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; Zepsyre (lurbinectedin) for small cell lung cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA Key Recent Developments

Jul 29,2019: PharmaMar announces results for the first half of 2019

Jul 29,2019: Pharma Mar announces change in composition of-the board of directors

Apr 26,2019: PharmaMar Group reports results for the first quarter of 2019

Apr 09,2019: PharmaMar announces its new immunotherapy research program

Mar 26,2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Pharma Mar SA-Key Facts

Pharma Mar SA-Key Employees

Pharma Mar SA-Key Employee Biographies

Pharma Mar SA-Major Products and Services

Pharma Mar SA-History

Pharma Mar SA-Company Statement

Pharma Mar SA-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Pharma Mar SA-Business Description

Business Segment: Biopharmaceuticals

Overview

Performance

Business Segment: Consumer Chemicals

Overview

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Italy

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Rest of the European Union

Performance

Geographical Segment: Rest of the World

Performance

Geographical Segment: Spain

Performance

Geographical Segment: the US

Performance

R&D Overview

Pharma Mar SA-SWOT Analysis

SWOT Analysis-Overview

Pharma Mar SA-Strengths

Pharma Mar SA-Weaknesses

Pharma Mar SA-Opportunities

Pharma Mar SA-Threats

Pharma Mar SA-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Pharma Mar SA, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 29, 2019: PharmaMar announces results for the first half of 2019

Jul 29, 2019: Pharma Mar announces change in composition of-the board of directors

Apr 26, 2019: PharmaMar Group reports results for the first quarter of 2019

Apr 09, 2019: PharmaMar announces its new immunotherapy research program

Mar 26, 2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)

Mar 21, 2019: PharmaMar: Soft Tissue Sarcoma requires a multidisciplinary approach to reduce patient relapses and improve patient survival

Feb 28, 2019: PharmaMar Group reports 2018 results

Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018

Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development

Aug 13, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Pharma Mar SA, Performance Chart (2014-2018)

Pharma Mar SA, Ratio Charts

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Pharma Mar SA, Key Facts

Pharma Mar SA, Key Employees

Pharma Mar SA, Key Employee Biographies

Pharma Mar SA, Major Products and Services

Pharma Mar SA, History

Pharma Mar SA, Subsidiaries

Pharma Mar SA, Key Competitors

Pharma Mar SA, Ratios based on current share price

Pharma Mar SA, Annual Ratios

Pharma Mar SA, Annual Ratios (Cont...1)

Pharma Mar SA, Annual Ratios (Cont...2)

Pharma Mar SA, Interim Ratios

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Pharma Mar SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pharma Mar SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Ability Pharmaceuticals SL

Ariad Pharmaceuticals (Spain) SL

GP Pharm SA

Traslational Cancer Drugs Pharma SL

CTI BioPharma Corp

Oryzon Genomics SA

Company Profile

Company Profile Title

Pharma Mar SA (PHM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; Zepsyre (lurbinectedin) for small cell lung cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA Key Recent Developments

Jul 29,2019: PharmaMar announces results for the first half of 2019

Jul 29,2019: Pharma Mar announces change in composition of-the board of directors

Apr 26,2019: PharmaMar Group reports results for the first quarter of 2019

Apr 09,2019: PharmaMar announces its new immunotherapy research program

Mar 26,2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Pharma Mar SA-Key Facts

Pharma Mar SA-Key Employees

Pharma Mar SA-Key Employee Biographies

Pharma Mar SA-Major Products and Services

Pharma Mar SA-History

Pharma Mar SA-Company Statement

Pharma Mar SA-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Pharma Mar SA-Business Description

Business Segment: Biopharmaceuticals

Overview

Performance

Business Segment: Consumer Chemicals

Overview

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Italy

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Rest of the European Union

Performance

Geographical Segment: Rest of the World

Performance

Geographical Segment: Spain

Performance

Geographical Segment: the US

Performance

R&D Overview

Pharma Mar SA-SWOT Analysis

SWOT Analysis-Overview

Pharma Mar SA-Strengths

Pharma Mar SA-Weaknesses

Pharma Mar SA-Opportunities

Pharma Mar SA-Threats

Pharma Mar SA-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Pharma Mar SA, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 29, 2019: PharmaMar announces results for the first half of 2019

Jul 29, 2019: Pharma Mar announces change in composition of-the board of directors

Apr 26, 2019: PharmaMar Group reports results for the first quarter of 2019

Apr 09, 2019: PharmaMar announces its new immunotherapy research program

Mar 26, 2019: PharmaMar to attend the China Healthcare Investment Conference (CHIC)

Mar 21, 2019: PharmaMar: Soft Tissue Sarcoma requires a multidisciplinary approach to reduce patient relapses and improve patient survival

Feb 28, 2019: PharmaMar Group reports 2018 results

Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018

Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development

Aug 13, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Pharma Mar SA, Performance Chart (2014-2018)

Pharma Mar SA, Ratio Charts

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Pharma Mar SA, Key Facts

Pharma Mar SA, Key Employees

Pharma Mar SA, Key Employee Biographies

Pharma Mar SA, Major Products and Services

Pharma Mar SA, History

Pharma Mar SA, Subsidiaries

Pharma Mar SA, Key Competitors

Pharma Mar SA, Ratios based on current share price

Pharma Mar SA, Annual Ratios

Pharma Mar SA, Annual Ratios (Cont...1)

Pharma Mar SA, Annual Ratios (Cont...2)

Pharma Mar SA, Interim Ratios

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Pharma Mar SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pharma Mar SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Ability Pharmaceuticals SL

Ariad Pharmaceuticals (Spain) SL

GP Pharm SA

Traslational Cancer Drugs Pharma SL

CTI BioPharma Corp

Oryzon Genomics SA